IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
Li, Zhenxiang; Jiang, Leilei; Bai, Hua; Wang, Zhijie; Zhao, Jun; Duan, Jianchun; Yang, Xiaodan; An, Tongtong; Wang, Jie
关键词BRAF mutation EGFR mutation lung adenocarcinomas plasma DNA
刊名THORACIC CANCER
2015-05-01
DOI10.1111/1759-7714.12177
6期:3页:269-274
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Respiratory System
研究领域[WOS]Oncology ; Respiratory System
关键词[WOS]FACTOR RECEPTOR MUTATIONS ; CANCER ; EGFR ; KRAS ; MANAGEMENT ; MELANOMA ; FEATURES
英文摘要

BackgroundThe purpose of this study was to investigate the prevalence, distribution, and prognostic role of v-raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutations in Chinese patients with lung adenocarcinoma (ADC), and to explore the possibility of BRAF V600E mutation detection in plasma DNA.

MethodsData from 190 patients with lung ADCs treated at the Peking University Cancer Hospital from July 2011 to March 2012 were collected. The amplification refractory mutation system was used for BRAF V600E testing and denaturing high-performance liquid chromatography for epidermal growth factor receptor (EGFR) mutation detection. In BRAF V600E-mutant cases, paired plasma DNA was tested for mutation status of BRAF V600E and EGFR. The distribution and prognostic role of BRAF V600E mutations were analyzed using SPSS 13.0.

ResultsAmong 190 patients with advanced lung ADC, eight (4.2%) cases carried BRAF V600E mutations. V600E mutations presented more frequently in women than in men (6 of 96, 6.3% vs. P = 0.1). BRAF and EGFR mutations were concomitantly presented in three patients. Five of the eight patients with BRAF V600E mutations had matched plasma DNA samples and V600E mutations were found in three plasma samples.

ConclusionThe prevalence of BRAF V600E mutations in Chinese patients with lung ADC is 4.2%. Circulating plasma DNA may be used for BRAF V600E mutation analysis in lung adenocarcinoma.

语种英语
WOS记录号WOS:000353922500006
项目编号81025012 ; 81172235 ; 2007-1023 ; 2011-2-22 ; Z090507017709015
资助机构National Natural Sciences Foundation Distinguished Young Scholars Program ; National Natural Sciences Foundation General Program ; Capital Development Foundation ; Beijing Health Systems Academic Leader Program ; Science and Technology Project of Beijing
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66982
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_胸部肿瘤内科
作者单位Peking Univ, Sch Oncol, Dept Thorac Med Oncol,Minist Educ, Beijing Canc Hosp & Inst,Key Lab Carcinogenesis &, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Li, Zhenxiang,Jiang, Leilei,Bai, Hua,et al. Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma[J]. THORACIC CANCER,2015,6(3):269-274.
APA Li, Zhenxiang.,Jiang, Leilei.,Bai, Hua.,Wang, Zhijie.,Zhao, Jun.,...&Wang, Jie.(2015).Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.THORACIC CANCER,6(3),269-274.
MLA Li, Zhenxiang,et al."Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma".THORACIC CANCER 6.3(2015):269-274.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Zhenxiang]的文章
[Jiang, Leilei]的文章
[Bai, Hua]的文章
百度学术
百度学术中相似的文章
[Li, Zhenxiang]的文章
[Jiang, Leilei]的文章
[Bai, Hua]的文章
必应学术
必应学术中相似的文章
[Li, Zhenxiang]的文章
[Jiang, Leilei]的文章
[Bai, Hua]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。